About Us

Precision IBD, the processor to Prometheus Biosciences was founded in 2016 by Scott Glenn and Stephan Targan, MD, who previously co-founded Santarus and Prometheus Laboratories. Prometheus Biosciences will serve as the name for the combined companies Precision IBD and Prometheus Laboratories, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD. Prometheus Biosciences’ mission is to address unmet medical needs for GI diseases and disorders including ulcerative colitis (UC) and Crohn’s disease (CD).

Leadership

Board of Directors

Scientific Advisors